- Previous Close
2.3000 - Open
2.3100 - Bid --
- Ask --
- Day's Range
2.3100 - 2.3100 - 52 Week Range
2.2000 - 5.2000 - Volume
218 - Avg. Volume
5,970 - Market Cap (intraday)
3.562M - Beta (5Y Monthly) 2.31
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5700 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
www.xeneticbio.comRecent News: XBIO
View More
Performance Overview: XBIO
Trailing total returns as of 4/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XBIO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XBIO
View MoreValuation Measures
Market Cap
3.55M
Enterprise Value
-2.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.42
Price/Book (mrq)
0.59
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-158.39%
Return on Assets (ttm)
-30.02%
Return on Equity (ttm)
-50.12%
Revenue (ttm)
2.5M
Net Income Avi to Common (ttm)
-3.96M
Diluted EPS (ttm)
-2.5700
Balance Sheet and Cash Flow
Total Cash (mrq)
6.17M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.19M